Catalent’s Indiana plant to make Novo’s Wegovy weight-loss drug  | Reuters News Agency


Reuters exclusively reported that Novo Nordisk has hired Thermo Fisher as its second contract manufacturer for its hugely popular weight-loss drug Wegovy. Novo Chief Financial Officer Karsten Munk Knudsen told Reuters in May the company had signed up a second contract manufacturer in the United States, but the identity of the company has not previously been reported. This was followed by another exclusive that Catalent’s plant in Bloomington, Indiana, will fill injection pens for Novo Nordisk’s  Wegovy as part of the two companies’ expanded supply agreement. Catalent’s shares briefly jumped on the news. 

Market Impact

Shares in Thermo jumped as much as 4% during New York trading on Wednesday. 

Article Tags

Topics of Interest: Health

Type: Reuters Best

Sectors: Pharmaceuticals & Healthcare

Regions: Americas

Countries: United States

Win Types: Exclusivity

Story Types: Exclusive / Scoop

Media Types: Text

Customer Impact: Significant National Story

Similar Posts

Leave a Reply

Your email address will not be published. Required fields are marked *